ArticleProbiotics and antimicrobial proteins2025
Synthesis, Characterization, and Biomedical Applications of Bacteriocin-Selenium Nanoconjugates.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioactivity of green-synthesized zinc oxide nanoparticles using Fusarium oxysporum extract on the expression of extended-spectrum beta-lactamase and biofilm-associated genes in the pathogen Klebsiella pneumoniae.Journal, genetic engineering & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antibiotic overuse in hospitals, the food industry, and animal feed over past times has led to a significant rise in the incidence of antibiotic-resistant bacteria. To address these potentially life-threatening antibiotic-resistant illnesses, a quick identification and development of novel antimicrobials are necessary. The aim of this study was to synthesize a novel bacteriocin-nanoconjugates by combining selenium nanoparticles with purified bacteriocin from the Enterococcus faecium SMAA23 and investigate some of its biomedical activities. The nanoconjugates were characterized via X-ray diffraction (XRD), transmission electron microscopy (TEM), energy dispersive X-ray desorption (EDX), and zeta potential analytical techniques. There is investigation of the antibacterial, antifungal, and anticancer properties of nanoconjugates. Purified bacteriocin has a known molecular weight of approximately 43,000 Daltons. The characterization of nanoparticles and nanoconjugates was performed. The crystallite size of nanoconjugate was determined via X-ray diffraction (XRD) to be 15.29 nm. Transmission electron microscopy (TEM) detected particles of irregular form of nanoconjugate, measuring between 11 and 24 nm in diameter. Energy dispersive X-ray spectroscopy (EDX) confirmed the presence of selenium and protein. The measured zeta potential was - 12.1 + 0.12 mV. The results revealed potent antibacterial activity against Acinetobacter baumannii, with a growth inhibition zone of 23 mm ± SD. A minimum inhibitory concentration (MIC) of nanoconjugate was 15.625 µg/mL, while a minimum bactericidal concentration (MBC) was 31.25 µg/mL. The application of scanning electron microscopy (SEM) enhanced the rupture of the bacterial cell wall. The antifungal activity against C. albicans and C. tropicalis resulted in growth inhibition zones of 14 mm and 16 mm (± SD), respectively. Various concentrations of the nanoconjugate strongly inhibited MDA-MB-231 cells in the MTT experiment. The novel synthesized bacteriocin-nanoconjugates exhibited substantial antibacterial, antifungal, and anticancer properties.
Indexed as
Identifiers
39658757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.